Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.570
+0.0801.46%
Volume:37.01M
Turnover:206.03M
Market Cap:104.06B
PE:36.70
High:5.620
Open:5.400
Low:5.400
Close:5.490
52wk High:8.442
52wk Low:4.136
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:1.50
T/O Rate:0.20%
Dividend:0.12
Dividend Rate:2.20%
EPS(LYR):0.152
ROE:14.07%
ROA:7.51%
PB:2.73
PE(LYR):36.70
PS:2.64

Loading ...

SBP Group Reports No Share Changes in August; 14.60 Million Shares Earmarked for Future M&A Payout

Bulletin Express
·
Sep 01

Sino Biopharma Unit Enters License, Supply Contract for Cancer Drug

MT Newswires Live
·
Aug 31

SBP Group inks exclusive pact with Cipla for novel HER2-targeting ADC

Stock News
·
Aug 31

Sino Biopharma Licenses HER2 ADC Tqb2102 to Cipla for India, South Africa, Other Emerging Markets in Deal Worth up to USD 123 Million

Reuters
·
Aug 31

Sino Biopharmaceutical - Cipla Granted Exclusive License for Tqb2102 in India, South Africa and Five Markets

THOMSON REUTERS
·
Aug 31

Sino Biopharmaceutical - Group Eligible for up to $123 Mln in Milestone Payments and Tiered Double-Digit Royalties

THOMSON REUTERS
·
Aug 31

Cipla and SBP Group Sign Exclusive Licensing Agreement for HER2 Bispecific Antibody-Drug Conjugate

Reuters
·
Aug 31

Sino Biopharmaceutical Stock Sheds 2.6% in Hong Kong

Dow Jones
·
Aug 31

Movement Alert|SBP GROUP Falls 3.04% in Regular Trading, Trading at HK$5.425

Market Focus
·
Aug 31

SBP Group Unveils Phase I Data: Single-Dose Kylo-11 Achieves Up to 97% Sustained Lp(a) Reduction

Bulletin Express
·
Aug 31

SBP Group Secures NMPA and FDA Green Lights for LM-364 “Nectin-4TME ADC” Clinical Trials

Bulletin Express
·
Aug 28

Sino Biopharm Wins NMPA Nod to Start LM-364 Nectin-4 TME ADC Trial in Solid Tumors

Reuters
·
Aug 28

Sino Biopharmaceutical - Lm-364 'Nectin-4Tme ADC' Receives Nmpa Clinical Trial Approval for Advanced Solid Tumors

THOMSON REUTERS
·
Aug 28

Movement Alert|SBP GROUP Falls 3.05% in Regular Trading, Trading at HK$5.545

Market Focus
·
Aug 27

China's Innovative Weight-Loss Patch Receives US Clinical Trial Approval

Deep News
·
Aug 26

Sino Biopharmaceutical Stock Climbs 2.1% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 26

Movement Alert|SBP GROUP Rises 3.29% in Regular Trading, GLP-1 Weight Management Microneedle Patch Receives US FDA Clinical Trial Approval

Market Focus
·
Aug 26

Sino Biopharma Wins FDA Clearance to Start Trial of Cpx301 GLP-1 Weight-Loss Microneedle Patch

Reuters
·
Aug 25

Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$8.67 From HK$8.26, Keeps at Buy

MT Newswires Live
·
Aug 24

Sino Biopharmaceutical (SEHK:1177) Could Be 66% Below Fair Value As Earnings Lift Interest

Simply Wall St.
·
Aug 22